LncRNA RPL29P2 promotes peritoneal fibrosis and impairs peritoneal transport function via miR-1184 in peritoneal dialysis

Peritoneal dialysis (PD), hemodialysis and kidney transplantation are the three therapies to treat uremia. However, PD is discontinued for peritoneal membrane fibrosis (PMF) and loss of peritoneal transport function (PTF) due to damage from high concentrations of glucose in PD fluids (PDFs). The mec...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of medical sciences Vol. 21; no. 6; pp. 1049 - 1063
Main Authors Li, Huan, Zhang, Yuting, Che, Mingwen, Wang, Hanmin, Li, Sutong, He, Peng, Sun, Shiren, Xu, Guoshuang, Huang, Chen, Liu, Xiaowei, Bai, Ming, Zhou, Meilan, Su, Binxiao, Zhang, Peng, He, Lijie
Format Journal Article
LanguageEnglish
Published Australia Ivyspring International Publisher 01.01.2024
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Peritoneal dialysis (PD), hemodialysis and kidney transplantation are the three therapies to treat uremia. However, PD is discontinued for peritoneal membrane fibrosis (PMF) and loss of peritoneal transport function (PTF) due to damage from high concentrations of glucose in PD fluids (PDFs). The mechanism behind PMF is unclear, and there are no available biomarkers for the evaluation of PMF and PTF. Using microarray screening, we found that a new long noncoding RNA (lncRNA), RPL29P2, was upregulated in the PM (peritoneal membrane) of long-term PD patients, and its expression level was correlated with PMF severity and the PTF loss. and rat model assays suggested that lncRNA RPL29P2 targets miR-1184 and induces the expression of collagen type I alpha 1 chain (COL1A1). Silencing RPL29P2 in the PD rat model might suppress the HG-induced phenotypic transition of Human peritoneal mesothelial cells (HPMCs), alleviate HG-induced fibrosis and prevent the loss of PTF. Overall, our findings revealed that lncRNA RPL29P2, which targets miR-1184 and collagen, may represent a useful marker and therapeutic target of PMF in PD patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Authors contributed equally to this work.
Competing Interests: The authors have declared that no competing interest exists.
ISSN:1449-1907
1449-1907
DOI:10.7150/ijms.93547